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ml provided optimal test accuracy to predict successful 
cardioversion.
Conclusion In patients with < 24 h of symptomatic AF, NT-
proBNP levels up to 1550 pg/ml correlate with high success 
rates (94 %) of cardioversion with flecainide. Conversely, 
NT-proBNP higher than 1550 pg/ml correlates with poor 
success rates (36 %). Further research is needed to validate 
the predictive value of NT-proBNP for successful cardio-
version with flecainide.
Introduction
Atrial fibrillation (AF) is one of the most common cardiac 
arrhythmias occurring in nearly 2 % of the general popula-
tion [1]. Its prevalence is expected to increase in the future 
due to ageing [2, 3]. AF is associated with higher risk of 
death, heart failure, stroke, and hospitalisations and lower 
quality of life [4, 5]. In the aspect of AF therapy, rate con-
trol (i.e., restriction of the ventricular rate < 110 beats per 
minute) has been shown to be not inferior to rhythm control 
(i.e., restoring and maintaining sinus rhythm [SR]) in reduc-
ing the risk for mortality and morbidity and in improving 
the quality of life [6, 7]. However, patients with AF may be 
haemodynamically severely compromised in the acute set-
ting or may remain symptomatic despite adequate rate con-
trol. In such cases, restoring SR is often (urgently) required 
[1].
SR can be achieved with direct current cardioversion 
(DCC) or antiarrhythmic drugs. DCC is an effective method 
of cardioversion with success rates of up to 94 %. However, 
it has potential disadvantages including the need for a fast-
ing state and general anaesthesia and the risk of complica-
tions such as skin burns, and hypoxia and hypoventilation 
due to sedation [8]. Pharmacological cardioversion with 
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antiarrhythmic drugs has the advantage of being simple, 
convenient and free of the need for a fasting state and anaes-
thesia. However, compared with DCC, success rates of 
pharmacological cardioversion are often remarkably lower 
[8, 9]. Moreover, antiarrhythmic drugs may induce arrhyth-
mias such as bradycardia, sinus node arrest, atrioventricular 
block, and ventricular tachyarrhythmias through their pro-
arrhythmic effects, and exaggerate (yet undiagnosed) heart 
failure through their negative inotropic effects [1, 8, 9]. 
Unfortunately, validated markers to predict the success of 
pharmacological cardioversion are lacking [10−13]. Identi-
fication of such markers may help clinicians to select their 
patients more adequately and, by doing so, increase success 
rates of pharmacological cardioversion and decrease the 
risk of serious adverse effects.
Plasma levels of B-type natriuretic peptide (BNP), and in 
particular its inactive N-terminal prohormone fragment (NT-
proBNP), are reported to be elevated in AF and to rapidly 
decrease after restoration of SR [14−17]. However, contra-
dictory data have been published on the role of NT-proBNP 
as a possible marker to predict the success of cardioversion 
[17−21]. Moreover, there are currently no data available on 
the use of plasma NT-proBNP level as a marker to predict 
the outcome of pharmacological cardioversion in patients 
with symptomatic AF. We therefore aimed to evaluate the 
predictive value of baseline plasma NT-proBNP level for 
successful cardioversion with flecainide in patients with 
< 24 h symptomatic AF (i.e., acute onset with AF symptoms 
lasting less than 24 h).
Methods
Study population and clinical data collection
In this prospective single-centre study, all adult patients 
(≥ 18 years of age) who presented to the cardiac emer-
gency room of the Tergooi Hospitals between January 2011 
and December 2012 with a primary diagnosis of AF were 
enrolled. Upon presentation, history was obtained, physi-
cal examination was performed, 12-lead electrocardiograms 
(ECGs) were taken, and baseline blood samples were drawn. 
If available, data on medical history were retrieved from 
hospital (electronic) patient records. Patients were excluded 
in the presence of one of the following criteria: permanent 
AF, symptoms lasting ≥ 24 h, supraventricular tachycardia 
other than AF on the ECG, haemodynamic instability, signs 
of heart failure, and ECG signs of acute or prior myocar-
dial infarction, including ST-segment elevation, low QRS 
voltages, intraventricular conduction disturbances and/or 
pathological Q waves. Criteria used to detect these ECG 
changes were as described earlier by the Third Universal 
Definition of Myocardial Infarction (see reference 22). The 
study was approved by the institutional review committees 
and conforms to the principles outlined in the Declaration 
of Helsinki. The following clinical data were collected from 
all included patients: age, gender, smoking, medication 
use, history of thyroid disease, and CHA2DS2-VASc score 
(history of congestive heart failure, hypertension, diabetes, 
thromboembolic events, and vascular disease). The follow-
ing data were collected from physical examination: heart 
rate, blood pressure, body weight and height, and whether 
clinical signs of congestive heart failure were present.
Cardioversion
All included patients received intravenous flecainide under 
continuous haemodynamic and ECG monitoring during 
drug administration and for at least 6 h afterwards. Fle-
cainide was administered in a dose of 2 mg per kg body 
weight (with a maximum dose of 150 mg) over 10 min. 
Patients in whom SR could not be obtained within 6 h after 
intravenous administration of flecainide underwent DCC. 
During these 6 h, patients were given nil per os instructions 
to reach a fasting state required for possible DCC. Patients 
who underwent DCC stayed under continuous monitor-
ing for at least 3 h before they were allowed to leave the 
hospital.
ECG analysis
Twelve-lead ECGs were made at baseline (upon presenta-
tion), during and after intravenous administration of fle-
cainide, and after restoration of SR. If patients underwent 
DCC, 12-lead ECGs were performed before and immedi-
ately after the procedure. Twelve-lead ECGs were taken 
from all patients upon discharge. ECGs were analysed by 
individuals blinded to NT-proBNP levels and cardioversion 
outcome.
Blood testing
Blood samples were drawn upon presentation and used to 
measure baseline plasma levels of haemoglobin, leuko-
cytes, C-reactive protein, creatinine, glucose, NT-proBNP, 
and thyroid hormone profile. All laboratory measurements, 
including NT-proBNP, were performed by the hospital 
central laboratory according to the hospital standards and 
quality.
Follow-up
Patients were scheduled for an outpatient follow-up 
appointment approximately 2 weeks after discharge, which 
included 12-lead ECG and echocardiography. Echocardio-
grams were used to measure left ventricular function and 
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be obtained with flecainide (P < 0.001; Table 1 and Fig. 1a). 
Left atrial diameter was significantly larger in patients 
who did not convert to SR than patients who obtained SR 
after flecainide (P = 0.019). The logistic regression model 
included the following patient characteristics as covariates 
(P < 0.20 at univariate analysis): age, heart rate, history of 
thyroid disease, left atrial diameter and log NT-proBNP. 
Logistic regression analysis indicated log NT-proBNP as 
the only independent predictor of cardioversion outcome 
with flecainide (P = 0.002). Left atrial diameter did not reach 
statistical significance as an independent predictor of car-
dioversion outcome (P = 0.078).
Figure 1b shows the ROC curve for baseline plasma NT-
proBNP levels as a predictor of outcome after cardiover-
sion with flecainide. The area under the curve was 0.8797 
(95 % confidence interval 07932–0.9663; P < 0.001). An 
analysis of cut-offs of baseline plasma NT-pro-BNP levels 
was carried-out. NT-proBNP levels lower than 1550 pg/
ml had a sensitivity of 95 % and a specificity of 60 %, and 
provided optimal predictive values for the outcome of car-
dioversion. In our study population, 98 patients had plasma 
NT-proBNP levels lower than 1550 pg/ml. Of these patients, 
92 (94 %) converted to SR with flecainide. These data indi-
cate that plasma NT-proBNP levels lower than 1550 pg/
ml correlate with a success rate of 94 % for cardioversion 
with flecainide (i.e., positive predictive value of 94 %). Con-
versely, 14 patients had plasma NT-proBNP levels higher 
than 1550 pg/ml, of whom only five (36 %) converted to 
SR with flecainide (i.e., negative predictive value of 64 %).
Medication use before and after cardioversion
At baseline, use of antiarrhythmic drugs was not different 
between patients with successful cardioversion with fle-
cainide and patients in whom SR could not obtained with 
flecainide (Table 1). The antiarrhythmic drug regimen was 
not changed after cardioversion or at discharge. At baseline, 
oral anticoagulation therapy had already been initiated in 
patients with prior episodes of AF and CHA2DS2-VASc ≥ 1 
(Table 1), except for female patients with gender as the only 
risk factor for stroke (n = 5). In all patients with AF de novo 
and CHA2DS2-VASc ≥ 1 (n = 44), oral anticoagulation ther-
apy was initiated at the time of hospital discharge (Table 1).
Discharge and follow-up
No clinical adverse effects and arrhythmias that could be 
related to flecainide were observed during monitoring after 
cardioversion. All patients had SR at the time of hospital 
discharge. At follow-up 2 weeks after hospital discharge, 
96 patients still had SR (86 %), while AF had recurred in 
the remaining 16 patients (14 %) (Table 1). Out of the 97 
patients with successful cardioversion with flecainide, 81 
left atrial diameter. ECGs and echocardiograms were anal-
ysed by individuals blinded to NT-proBNP levels and car-
dioversion outcome.
Statistics
Categorical variables are presented as frequencies and per-
centages and were compared by χ2 test or Fisher’s exact test, 
where appropriate. Continuous variables are presented as 
means with standard error (SEM) if normally distributed or 
as medians with interquartile range (IQR) if otherwise, and 
were compared by unpaired t tests or the Mann−Whitney 
U-test, respectively. Because of the skewed distribution of 
NT-proBNP, logarithmic transform (log NT-proBNP) was 
computed to approach a normal distribution, which was 
confirmed by the Kolmogorov−Smirnov test. The indepen-
dent effect of multiple variables on outcome of cardiover-
sion with flecainide and on plasma NT-proBNP levels was 
tested using univariate analysis. All variables with a P < 0.20 
at univariate analysis were selected for multivariate logistic 
regression analysis. The diagnostic utility of plasma NT-
proBNP for predicting the outcome of cardioversion with 
flecainide was assessed by obtaining a receiver operating 
characteristic (ROC) curve. Statistical significance was 
defined as P < 0.05. Statistical analyses were performed 
using SPSS (Chicago, Illinois, USA).
Results
Study population
In total, 112 patients met the inclusion criteria and under-
went pharmacological cardioversion with intravenous fle-
cainide. Cardioversion with flecainide was successful in 
97 patients with < 24 h of symptomatic AF (87 %). In all 
the remaining 15 patients with < 24 h of symptomatic AF 
(13 %), in whom SR could not be obtained within 6 h after 
intravenous infusion of flecainide, SR could be achieved 
with DCC.
Baseline characteristics
Patient characteristics at baseline (before cardioversion) are 
displayed in Table 1. Age, proportion of men, body mass 
index, CHA2DS2-VASc score, drug use, and the prevalence 
of common conditions associated with AF (e.g., coronary 
artery disease, hypertension, diabetes, thyroid disease, and 
smoking) did not differ between patients with success-
ful cardioversion with flecainide and patients in whom SR 
could not be obtained with flecainide. However, baseline 
plasma NT-proBNP level was significantly lower in patients 
who converted to SR than in patients in whom SR could not 
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at follow-up (regardless of the outcome of cardioversion 
with flecainide; Table 2). Patient characteristics, including 
baseline plasma NT-proBNP level and left atrial diameter, 
also did not differ between patients with successful cardio-
version with flecainide who still had SR and patients with 
successful cardioversion with flecainide in whom AF had 
recurred at follow-up (Table 3). No thromboembolic com-
plications were found in any of the patients at follow-up.
Discussion
In this study, we aimed to evaluate the predictive value of 
baseline plasma NT-proBNP level for successful cardiover-
(84 %) still had SR at follow-up while in 16 patients (14 %) 
AF had recurred. All 15 patients in whom SR could not be 
obtained with flecainide and who had undergone success-
ful DCC had SR at follow-up. Characteristics of patients 
according to their heart rhythm at follow-up (SR or AF; 
regardless of the outcome of cardioversion with flecainide) 
are shown in Table 2. Characteristics of patients according 
to the outcome of cardioversion with flecainide and heart 
rhythm at follow-up (SR or AF) are shown in Table 3. Patient 
characteristics, including baseline plasma NT-proBNP level 
and left atrial diameter, did not differ between patients who 
had SR at follow-up and those in whom AF had recurred 
Table 1 Baseline characteristics of the study population at baseline according to the outcome of cardioversion with intravenous flecainide
All patients Conversion to SR after flecainide Persistence of AF after flecainidea p value
(n = 112) (n = 97) (n = 15)
Baseline
Age (years) 63 ± 1 62 ± 1 67 ± 3 0.151
Men (n, %) 60 (54) 50 (52) 10 (67) 0.415
Heart rate (beats/minute) 125 ± 2 126 ± 2 115 ± 7 0.147
Systolic blood pressure (mmHg) 139 ± 2 140 ± 2 134 ± 5 0.288
Diastolic blood pressure (mmHg) 86 ± 1 86 ± 2 85 ± 3 0.762
BMI > 25 kg/m2 (n, %) 31 (28) 25 (26) 6 (40) 0.403
AF de novo (n, %) 59 (53) 51 (53) 8 (53) 0.884
Coronary artery disease (n, %) 11 (10) 9 (9) 2 (13) 0.980
Hypertension (n, %) 52 (46) 47 (48) 5 (33) 0.415
Diabetes (n, %) 8 (7) 7 (7) 1 (7) 0.644
Thyroid disease 5 (4) 3 (3) 2 (13) 0.265
Current smoking (n, %) 24 (21) 21 (22) 3 (20) 0.847
Smoking history (n, %) 27 (24) 22 (23) 5 (33) 0.566
CHA2DS2-VASc 2 (1–3) 2 (1–3) 2 (0.25–3) 0.815
CHA2DS2-VASc ≥ 1 (n, %) 88 (79)
b 77 (79)b 11 (73) 0.847
CHA2DS2-VASc ≥ 1 & AF de novo (n, %) 44 (39) 40 (41) 4 (27) 0.429
Oral anticoagulation use (n, %) 39 (35) 32 (33) 7 (47) 0.457
Class I or III antiarrhythmic drugs (n, %) 18 (16) 14 (14) 4 (27) 0.411
Class II or IV antiarrhythmic drugs (n, %) 16 (14) 15 (15) 1 (7) 0.610
Haemoglobin (mmol/l) 9.2 ± 0.1 9.1 ± 0.1 9.2 ± 0.2 0.689
Leukocytes (× 109/l) 7.5 ± 0.2 7.5 ± 0.2 7.9 ± 0.4 0.338
C-reactive protein (mg/l) 5.4 ± 1.2 5.4 ± 1.3 5.5 ± 3.2 0.984
Normal glomerular filtration rate (n, %) 110 (98) 95 (98) 15 (100) 0.627
Glucose (mmol/l) 6.2 ± 0.1 6.3 ± 0.1 5.9 ± 0.4 0.213
Thyroid-stimulating hormone (mE/l) 2.4 ± 0.2 2.4 ± 0.2 3.2 ± 0.7 0.955
NT-ProBNP (pg/ml), mean (SEM) 612 ± 69 449 ± 52 1669 ± 263  < 0.001
NT-ProBNP (pg/ml), median (IQR) 316 [111–808] 266 [101–529] 1597 [779–2430]  < 0.001
Follow-up
SR at follow-up (n, %) 96 (86) 81 (84) 15 (100) 0.193
Left atrial size (mm) 40 ± 1 39 ± 1 43 ± 2 0.019
Left ventricular ejection fraction > 55 % (n) 112 (100 %) 97 (100 %) 15 (100 %) 1.000
N indicates number of patients. Data are presented as means ± standard error (SEM) or medians with interquartile range (IQR)
AF atrial fibrillation, SR sinus rhythm, BMI body mass index
a In all 15 patients in whom SR could not be obtained after intravenous infusion of flecainide, SR was achieved with direct current cardioversion 
(DCC)
b Five patients within this group with CHA2DS2-VASc ≥ 1 were female patients with gender as the only risk factor for stroke
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sion with flecainide in patients with < 24 h symptomatic AF. 
In 112 patients with AF and AF-related symptoms lasting 
less than 24 h, we found that: (1) patients who obtained SR 
after intravenous flecainide had significantly lower base-
line plasma NT-proBNP levels than patients in whom SR 
could not be obtained with flecainide, (2) baseline plasma 
NT-proBNP level is an independent predictor of immedi-
ate cardioversion outcome with intravenous flecainide, (3) 
baseline plasma NT-ProBNP levels lower than 1550 pg/ml 
correlate with a high cardioversion success rate (94 %), (4) 
cardioversion with flecainide has a poor success rate (36 %) 
in AF patients with baseline NT-ProBNP levels higher 
than 1550 pg/ml, and (5) baseline plasma NT-ProBNP lev-
els were not associated with maintenance of SR 2 weeks 
after successful cardioversion. We also found that left atrial 
diameter was significantly larger in patients in whom SR 
could not be obtained with flecainide than in patients with 
SR after intravenous administration of flecainide. However, 
left atrial diameter was not indicated as an independent 
predictor of cardioversion outcome by logistic regression 
Figure 1 Panel a displays baseline plasma NT-proBNP levels (upon 
admission) during atrial fibrillation in patients who converted to sinus 
rhythm (SR) versus those who did not convert to SR after intravenous 
administration of flecainide. N indicates number of patients. Panel b 
displays the receiver operating curve of plasma NT-pro-BNP levels as 
a predictor of outcome of cardioversion with intravenous flecainide. 
Panel c displays the proportion of patients who converted to SR after 
intravenous administration of flecainide who had baseline plasma NT-
proBNP levels lower than 1550 pg/ml or higher than 1550 pg/ml
 Table 2 Characteristics of the study population according to the heart 







(n = 96) (n = 16)
Conversion to SR with 
flecainide i.v.
81 (84) 16 (100) 0.193
Persistence of AF after 
flecainide i.v.
15 (16) 0 (100) 0.193
Age (years) 62 ± 7 66 ± 13 0.274
Men (n, %) 50 (52) 10 (63) 0.727
BMI > 25 kg/m2 (n, %) 29 (30) 2 (13) 0.244
AF de novo (n, %) 53 (55) 6 (38) 0.297
Coronary artery disease (n, %) 10 (10) 1 (6) 0.948
Hypertension (n, %) 45 (47) 7 (44) 0.969
Diabetes (n, %) 7 (7) 1 (6) 0.708
Thyroid disease 4 (4) 1 (6) 0.779
Current smoking (n, %) 22 (23) 2 (13) 0.541
Smoking history (n, %) 26 (27) 1 (6) 0.137
CHA2DS2-VASc 2 [1.0–3.0] 1.5 [1–2.5] 0.997
CHA2DS2-VASc ≥ 1 (n, %)
a 75 (78) 13 (81) 0.963
Oral anticoagulation use (n, %) 32 (33) 7 (44) 0.599
Class I or III antiarrhythmic 
drugs (n, %)
15 (16) 3 (19) 0.958
Class II or IV antiarrhythmic 
drugs (n, %)
15 (16) 1 (6) 0.544
NT-ProBNP (pg/ml), mean 
(SEM)
637 ± 78 465 ± 109 0.384







Left atrial size (mm) 39 ± 0 40 ± 1 0.801
Left ventricular ejection 
fraction > 55 % (n)
96 (100 %) 16 (100) 1.000
N indicates number of patients. Data are presented as means ± 
standard error (SEM) or medians with interquartile range (IQR)
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left ventricular function, shorter AF duration, use of class 
I or III antiarrhythmic drugs, and lower plasma levels of 
C-reactive protein [10−13]. However, as was confirmed by 
this study, none of these factors has been shown as a reliable 
and useful predictor of successful cardioversion.
BNP and NT-proBNP are produced in both the atria and 
the ventricles. Their release is mainly stimulated by myocar-
dial wall stress. Plasma levels of BNP and NT-proBNP are 
reported to be elevated in AF, to predict occurrence of AF 
de novo and to decrease after restoration of SR [14−17, 24]. 
This elevation is speculated to result from atrial stretch due 
to atrial overload during AF. Contradictory data have been 
published regarding the role of plasma BNP and NT-proBNP 
levels as predictors of successful cardioversion [17−21]. 
However, most of the previous studies were performed in a 
small number of patients with variable duration of AF (days 
to months) in whom structural heart diseases were excluded 
in advance. In our study, we evaluated the predictive value 
of plasma NT-proBNP for successful cardioversion in a set-
ting that closely resembles the daily clinical practice. To do 
so, we performed a study in patients who sought medical 
help for acute-onset AF-related symptoms by presenting 
analysis. Our data provide evidence that baseline plasma 
NT-proBNP level may be used as an easy, effective and safe 
marker to predict the immediate outcome of cardioversion 
with flecainide in patients with acute-onset < 24 h symptom-
atic AF. This may help to increase the cardioversion suc-
cess rates and decrease the risk of serious adverse effects. 
However, our data also suggest that baseline plasma NT-
proBNP levels do not predict long-term maintenance of SR 
after cardioversion.
Compared with DCC, pharmacological cardioversion 
has the advantage of being simple, convenient and free of 
the need for a fasting state and general anaesthesia. Unfor-
tunately, success rates of pharmacological cardioversion are 
lower than for DCC, ranging between 50 and 80 % [23]. In 
addition, antiarrhythmic drugs that are used for pharma-
cological cardioversion may exaggerate heart failure and 
increase the risk for arrhythmias such as bradycardia, sinus 
node arrest, atrioventricular block, and ventricular tachyar-
rhythmias [1, 8, 9]. Several factors have been associated 
with higher success rates of cardioversion (electrically or 
pharmacologically), including younger age, absence of 
structural heart disease, smaller left atrial diameter, normal 
Table 3 Characteristics of the study population according to the outcome of cardioversion with intravenous flecainide and according to the heart 
rhythm at follow-up
Conversion to SR after 
flecainide
SR at follow-up
Conversion to SR after 
flecainide
AF at follow-up
p value Persistence of AF after 
flecainidea
SR at follow-up
(n = 81) (n = 16) (n = 15)
Age (years) 62 ± 1 66 ± 3 0.206 67 ± 3
Men (n, %) 40 (49) 10 (63) 0.493 10 (67)
BMI > 25 kg/m2 (n, %) 23 (28) 2 (13) 0.227 6 (40)
AF de novo (n, %) 45 (56) 6 (38) 0.259 8 (53)
Coronary artery disease (n, %) 8 (10) 1 (6) 1.000 2 (13)
Hypertension (n, %) 40 (49) 7 (44) 0.890 5 (33)
Diabetes (n, %) 6 (7) 1 (6) 1.000 1 (7)
Thyroid disease 2 (2) 1 (6) 0.421 2 (13)
Current smoking (n, %) 19 (23) 2 (13) 0.510 3 (20)
Smoking history (n, %) 21 (26) 1 (6) 0.109 5 (33)
CHA2DS2-VASc 2 [1–3] 1.5 [1–2.5] 0.981 2 (0.25–3)
CHA2DS2-VASc ≥ 1 (n, %)
a 64 (79)b 13 (81) 1.000 11 (73)
Oral anticoagulation use (n, %) 25 (31) 7 (44) 0.477 7 (47)
Class I or III antiarrhythmic drugs (n, %) 11 (14) 3 (19) 0.697 4 (27)
Class II or IV antiarrhythmic drugs (n, %) 14 (17) 1 (6) 0.453 1 (7)
NT-ProBNP (pg/ml), mean (SEM) 445 ± 58 465 ± 109 0.891 1669 ± 263
NT-ProBNP (pg/ml), median (IQR) 266 [94–510] 344 [152–693] 0.443 1597 (779–2430)
Left atrial size (mm) 39 ± 1 40 ± 1 0.546 43 ± 2
Left ventricular ejection fraction > 55 % (n) 81 (100) 16 (100) 1.000 15 (100 %)
N indicates number of patients. Data are presented as means ± standard error (SEM) or medians with interquartile range (IQR)
AF atrial fibrillation, SR sinus rhythm, BMI body mass index
a In all 15 patients in whom SR could not be obtained after intravenous infusion of flecainide, SR was achieved with direct current cardioversion 
(DCC)
b Five patients within this group with CHA2DS2-VASc ≥ 1 were female patients with gender as the only risk factor for stroke. P values indicate 
statistical difference between patients with successful cardioversion with flecainide who still had SR at follow-up and those with successful 
cardioversion with flecainide in whom AF had recurred
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to the cardiac emergency room. We included patients with 
symptoms lasting less than 24 h using flecainide for cardio-
version because of prior evidence of its greater efficacy to 
restore SR compared with other antiarrhythmic agents [23]. 
Probably, by using proper inclusion and exclusion criteria, 
we did not observe any serious adverse effects that could be 
related to flecainide. A high success rate of cardioversion 
(87 %) was therefore achieved. By using a cut-off value of 
1550 pg/ml for baseline plasma NT-proBNP, even a higher 
success rate of 94 % could be achieved, which is similar to 
success rates reported for DCC.
Flecainide is a class 1C antiarrhythmic drug which pos-
sesses the ability to block the cardiac sodium channel. 
Flecainide may also facilitate arrhythmias by slowing con-
duction of electrical stimuli through the heart [25, 26]. In 
patients with AF, the slowing of electrical conduction may 
be reflected as prolongation of QRS interval duration dur-
ing flecainide infusion. In our study, patients with prolonged 
QRS durations at baseline were excluded, and marked QRS 
interval prolongation or arrhythmias during and after fle-
cainide infusion were not observed during continuous ECG 
monitoring. However, we did not measure QRS interval 
durations at different time points during flecainide infusion, 
and thus cannot exclude subtle flecainide-induced QRS 
changes in our patients. In addition, it must be noted that all 
patients in our study had normal left ventricular function, 
and it remains to be investigated whether a NT-proBNP cut-
off value of 1550 pg/ml may also be used in patients with 
impaired left ventricular function, a condition that is also 
associated with elevated NT-proBNP levels.
In conclusion, this prospective single-centre study in 
patients with acute-onset (< 24 h) symptomatic AF, and 
no manifest signs of heart failure and cardiac ischaemia, 
showed that baseline plasma NT-ProBNP levels up to 
1550 pg/ml correlate with high success rates of cardiover-
sion with flecainide. Conversely, cardioversion with fle-
cainide had a poor success rate in patients with NT-ProBNP 
levels higher than 1550 pg/ml. Therefore, cardioversion 
with flecainide may be a highly effective and safe therapy 
in patients with acute-onset (< 24 h) symptomatic AF and 
baseline plasma NT-proBNP levels lower than 1550 pg/ml. 
Moreover, our data suggest that the indication for flecainide 
use for cardioversion in patients with < 24 h symptomatic 
AF and NT-ProBNP levels higher than 1550 pg/ml may be 
reconsidered. In addition, our data also suggest that baseline 
NT-proBNP levels may not predict long-term maintenance 
of SR after successful cardioversion. Further prospective 
studies in patients with AF are needed to validate our find-
ing concerning the predictive value of baseline plasma NT-
proBNP levels for successful cardioversion with flecainide 
in patients with acute-onset symptomatic AF.
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